Metallothionein levels in ovarian tumours before and after chemotherapy.
The metallothionein content of ovarian tumours is considerably higher than that found in normal ovaries (greater than 100-fold differences in mean values, P less than 0.001). There was no difference between the metallothionein content of tumours from patients who had completed chemotherapy, usually with a regimen containing a platinum drug, and tumours from untreated patients. Similarly, the level of metallothionein was not influenced by response to therapy, age, stage, histology, or tumour cell differentiation state. These data do not support the hypothesis that metallothionein content is a major determinant of tumour sensitivity in ovarian cancer.
Murphy
D
D
CRC Department of Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital, Withington, Manchester, UK.
McGown
A T
AT
Crowther
D
D
Mander
A
A
Fox
B W
BW
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008558:Melphalan / Q000008:administration & dosage; D008668:Metallothionein / Q000032:analysis*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000188:drug therapy; D010053:Ovary / Q000737:chemistry*
D004317:Doxorubicin; D003520:Cyclophosphamide; D008668:Metallothionein; D016190:Carboplatin; D008558:Melphalan; D007069:Ifosfamide